Squarepoint
LFCR icon

Squarepoint’s Lifecore Biomedical LFCR Stock Holding History

Squarepoint’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$487K Buy
92,674
+40,270
+77% +$203K ﹤0.01% 3449
2026
Q1 		$195K Sell
52,404
-58,095
-53% -$401K ﹤0.01% 3967
2025
Q4 		$904K Sell
110,499
-40,410
-27% -$299K ﹤0.01% 2708
2025
Q3 		$1.11M Buy
150,909
+119,851
+386% +$907K ﹤0.01% 2604
2025
Q2 		$252K Buy
31,058
+2,230
+8% +$15K ﹤0.01% 3810
2025
Q1 		$203K Buy
28,828
+18,755
+186% +$117K ﹤0.01% 4009
2024
Q4 		$74.8K Sell
10,073
-17,701
-64% -$113K ﹤0.01% 4763
2024
Q3 		$137K Buy
+27,774
New +$145K ﹤0.01% 3801
2023
Q3 		– Sell
-23,657
Closed -$229K – 4043
2023
Q2 		$229K Buy
+23,657
New +$144K ﹤0.01% 3136
2023
Q1 		– Sell
-17,789
Closed -$115K – 3524
2022
Q4 		$115K Buy
+17,789
New +$147K ﹤0.01% 2944
2022
Q1 		– Sell
-15,349
Closed -$170K – 3220
2021
Q4 		$170K Sell
15,349
-29,369
-66% -$285K ﹤0.01% 2770
2021
Q3 		$412K Buy
44,718
+3,525
+9% +$38.4K ﹤0.01% 2067
2021
Q2 		$463K Buy
41,193
+18,404
+81% +$212K ﹤0.01% 2189
2021
Q1 		$242K Sell
22,789
-62,681
-73% -$705K ﹤0.01% 2567
2020
Q4 		$927K Buy
85,470
+26,025
+44% +$269K 0.01% 1390
2020
Q3 		$578K Buy
+59,445
New +$566K 0.01% 1326
2020
Q1 		– Sell
-18,734
Closed -$212K – 2220
2019
Q4 		$212K Sell
18,734
-13,044
-41% -$139K ﹤0.01% 2201
2019
Q3 		$345K Buy
+31,778
New +$346K ﹤0.01% 1823

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Squarepoint's LFCR Position: Q2 2026 in Review

Squarepoint increased its Lifecore Biomedical (LFCR) stake by 77% in Q2 2026, buying an estimated $203K and bringing the position to 92,674 shares worth $487K. The position accounts for ﹤0.01% of the portfolio, ranked #3449.

Squarepoint first reported a position in LFCR in Q3 2019 and has held it in 18 quarters since. The position peaked at $1.11M in Q3 2025. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Squarepoint held 92,674 shares of Lifecore Biomedical worth $487K as of Q2 2026.
  • Squarepoint bought 40,270 Lifecore Biomedical shares in Q2 2026, an estimated $203K.
  • Lifecore Biomedical made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3449 holding.
  • Squarepoint first reported a position in Lifecore Biomedical in Q3 2019 and has held it in 18 quarters since.
  • Squarepoint's Lifecore Biomedical position peaked at $1.11M in Q3 2025.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.